Pfizer’s rogue exec strikes back
Executive Summary
Peter Rost files a wrongful termination suit against Pfizer, CEO Hank McKinnell and other senior executives Dec. 12. Rost's suit alleges the defendants violated the N.J. Conscientious Employee Protection Act, which prohibits companies from retaliating against whistleblowers. Pfizer terminated Rost, who held the title VP-marketing, Dec. 1 following the unsealing of a qui tam lawsuit in which Rost alleges Pharmacia promoted the human growth hormone product Genotropin off-label prior to Pifzer's acquisition of the company in 2003 (1"The Pink Sheet" Dec. 5, 2005, In Brief). The Boston U.S. Attorney chose not to intervene in the lawsuit. Rost has been an outspoken advocate of pharmaceutical importation...
You may also be interested in...
Pfizer fires “rogue” exec
Pfizer terminates VP-Marketing Peter Rost Dec. 1. Rost made headlines in 2004 when he publicly voiced support for pharmaceutical importation (1"The Pink Sheet" Sept. 27, 2004, p. 15). His termination follows the unsealing of a qui tam lawsuit in which Rost alleged Pharmacia violated the False Claims Act by promoting the human growth hormone product Genotropin off-label prior to Pfizer's acquisition of the firm in 2003. The Boston U.S. Attorney chose not to intervene on Rost's behalf in the case although governmental investigations into other aspects of Pharmacia's Genotropin promotion are ongoing, the company says...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: